Curanex Pharmaceuticals Inc (CURX)
| Market Cap | 210.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137,056 |
| Shares Out | 42.00M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CURX
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with u... [Read more]
News
Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO
Curanex Pharmaceuticals, a preclinical biopharma developing botanical-based treatments for various diseases, filed on Wednesday with the SEC to raise up to $10 million in an initial public offering.
Curanex Pharmaceuticals IPO Registration Document (S-1)
Curanex Pharmaceuticals has filed to go public with an IPO on the NASDAQ.